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Mendelian randomization (MR), a genetic epidemiological approach, has made substantial 
inroads into our understanding of the causes, and consequences, of disease (1, 2). 
Conventionally, MR takes genetic variants associated with an exposure to estimate the causal 
effect on risk of disease. Availability of large-scale data and hypothesis-free genome-wide 
analyses has led to discovery of trait-associated genetic variants that surpass stringent 
thresholds for multiple testing correction, making genome-wide association study (GWAS) 
discoveries among the most reliable (i.e. among the least prone to false positives) in the 
scientific literature. 
 
A naïve criticism of GWAS is that the discoveries made therein have limited translational utility. 
Combining GWAS-identified single nucleotide polymorphisms (SNPs) into genetic instruments 
under the MR approach, however, offers translational opportunities, yielding notable 
discoveries for public health and, in the longer-term, pharmaceutical development. More 
immediate translational opportunities include pharmacogenetics (3), and the emerging use of 
GWAS for disease prediction (4). In the case of MR, recent examples include identifying that 
genetic liability to diabetes causes erectile dysfunction (5), and that alcohol consumption may 
not protect from vascular disease (6). The elucidation of these would be seemingly unachievable 
under other study designs; e.g., the National Institutes of Health -funded Moderate Alcohol and 
Cardiovascular Health trial (MACH15; NCT03169530) was abandoned due to perceived influence 
and bias from Big Alcohol (7). As with all scientific investigations, MR studies can be influenced 
by unique forms of bias, confounding, and analytical inaccuracies – what differentiates MR from 
conventional epidemiology is the availability of multiple sensitivity analyses (8), enabling 
scientists to test many of the implicit assumptions. 
 
In this issue of Clinical Chemistry, Mohammadi-Shemirani and colleagues (9) have turned MR on 
its head. They propose taking a summary score of genetic variants robustly associated with 
estimated glomerular filtration rate (eGFR), a trait used to assess renal function, and have 
related this to a range of potential biomarkers. Taking 50 eGFR-associated SNPs in combination, 
they found an association with concentrations of the protein trefoil factor (TFF3). Importantly, 
cis-acting  protein quantitative trait loci (pQTLs) did not demonstrate a causal effect of TFF3 on 
eGFR, suggesting that the biomarker identified was not a cause, but possibly a consequence of 
eGFR. 
 
A disease-associated genetic risk score (GRS) would be expected to associate with causes of the 
disease, consequences of the process leading to the disease, or the disease itself. For example, a 
GRS for lung cancer that included CHRNA5 variants related to heaviness of smoking would be 
expected, therefore, to associate with smoking behavior. It is also possible that a GRS for a 
disease might identify biomarkers that are influenced by the process leading to disease or the 
disease itself. In this case, if MR of the biomarker suggests that the biomarker does not cause 
disease (as in the study by Mohammadi-Shemirani and colleagues(9)), the biomarker may be a 
good candidate to investigate for disease prediction.  
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What do biomarker-associations of SNPs combined into a GRS that were originally identified for 
disease (or a precursor of disease) actually mean? We consider these to represent at least seven 
scenarios (see Figure 1), which we elucidate below and in the Figure: note that we do not 
consider these to be exhaustive. Scenarios 1-4 represent ‘real’ GRS-to-trait associations, 
whereas scenarios 5-7 represent potential artifacts either due to analytical method, study 
design or diagnostic approach to disease.  
 
First, the biomarker association of the GRS may represent a biomarker that causes disease. An 
example of this would be PCSK9 genetic variants that associate with coronary heart disease 
(CHD) at GWAS significance, and which pinpoint LDL-cholesterol as being on the causal pathway 
to risk of CHD. A GRS-associated biomarker in this scenario may have predictive utility and could 
also represent a therapeutic target for disease prevention. 
Second, disease-GRS associations with a biomarker may represent a consequence of disease, 
akin to the conventional epidemiological phenomenon of ‘reverse causality’. For example, a GRS 
for CHD is associated with a higher likelihood of receiving statin therapy (analyzed in MR-
Base(10) on 8th December 2018). A naïve interpretation would be that statin therapy leads to a 
higher risk of CHD, but of course this is not the case: all individuals with CHD are prescribed 
statin therapy as first-line treatment. 
Third, the biomarker association may arise as a result of vertical pleiotropy of a genetic variant 
or variants that associate with a biomarker (e.g. biomarker X in Figure 1) that plays a causal role 
in disease, but where crucially the GRS-associated biomarker is not causally related to disease 
(biomarker X2 in Figure 1). For example, genetic variation in IL6R, which encodes the interleukin-
6 (IL6) receptor (IL6R) is a cause of CHD. Altered activity of the IL6R pathway leads to 
perturbations in circulating concentrations of both IL6 (which binds to IL6R) and C-reactive 
protein (CRP) (which IL6, acting through IL6R, modifies). A CHD GRS may identify CRP as 
associated in this situation as a result of such pleiotropy of the IL6R pathway – note that CRP is 
not a cause of CHD in this setting. In a similar way, biomarker associations due to vertical 
pleiotropy of SNPs in the GRS representing pathways arising from disease would lead to a similar 
association (e.g., the association of a GRS with biomarker Z2 as a result of vertical pleiotropy 
through Z in Figure 1) . 
Fourth, a biomarker association from a GRS may represent horizontal pleiotropy (11) of one or 
more genetic variants that also associate with disease. In this situation, one or more genetic 
variants would associate with the identified biomarker not either through a pathway leading to 
disease or arising from disease, but from another relationship altogether that is unrelated to 
disease. A biomarker identified in this scenario is unlikely to have any role in prediction, nor 
does it represent a valid therapeutic target for disease prevention or treatment. 
Fifth, the association may arise due to conditioning for a trait in the original GWAS (12). In using 
a GRS for type 2 diabetes (T2D), an inverse association with body mass index (BMI) may be 
identified, which is opposite to the well-recognized causal role of adiposity in T2D. However, 
conditioning on the original T2D GWAS for BMI would lead to selection of variants that on 
average increase liability to T2D but are associated with lower BMI.(13) On regressing these 
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SNPs onto phenotypes, an inverse association with BMI may be identified, purely as a result of 
the analytical model of the original T2D GWAS. 
Sixth, the association may be induced by selection biases affecting cases or controls. For 
example, if cases are identified from a screening program and controls are from the general 
population, selection biases into a screening program might identify associations of the GRS 
with socioeconomic factors such as years of education. 
Seventh, the biomarker leads to disease diagnosis but the biomarker itself is not causal. For 
example, increased prostate specific antigen (PSA) concentration is used to diagnose prostate 
cancer. Thus a GRS of prostate cancer may associate with PSA even in the absence of a causal 
effect of PSA on prostate cancer. 
 
In the current article (9), the focus was on the application of a pre-disease GRS to identify novel 
biomarkers for prediction. As the authors note, the ideal biomarker for prediction is one that is 
independently and strongly associated with a disease and which makes meaningful 
improvements to disease prediction – i.e. it need not be causal. In this case, out of the seven 
scenarios above, when might a biomarker be useful for prediction? Biomarker associations 
arising from horizontal pleiotropy of a genetic instrument is unlikely to have clinical utility, nor is 
an association that is induced by adjusting for a trait in the discovery GWAS, when there are 
selection biases present, or when diagnosis is based on a non-causal biomarker. The authors (9) 
tease apart potential sources of bias, and ultimately, are able to show that inclusion of TFF3 
leads to modest improvements in disease prediction: the c-statistic increasing from 0.59 to 0.60. 
Such measures of discrimination may be insensitive to small, but meaningful, increments in 
predictive utility (14). Comparatively, recent studies that incorporated genetic variants for 
prediction of CHD led to similar changes in area-under -the-curve, from c-statistics of 0.67 for 
conventional risk factors to 0.70 with inclusion of 1.7 million genetic variants (4). 
 
When might combinations of measured phenotype and/or its genotypic variation be useful in 
prediction? When a biomarker itself is causally related to disease, phenotypic measurements 
are likely to be useful beyond genotype, as the measured trait will additionally capture 
environmental variation (as it is the combined genetic and environmental variation in the causal 
biomarker that ultimately leads to disease). In this same scenario, genotype will also be useful in 
addition to the measured phenotype as genotype represents a measure of lifelong exposure. 
When the biomarker is a consequence of disease (i.e. the association arises from reverse 
causality), measuring the trait is of importance as it gives a dynamic ‘read out’ of disease status. 
Finally, when a biomarker is non-causal in disease, including genotype in the model may 
increase the predictive utility of the biomarker, through the principle of so-called “biomarker 
de-Mendelization”, by maximizing the non-genetic variation in the phenotype (15).  
 
With burgeoning technological advances in high throughput phenotyping of omics down-stream 
of the invariant genome (notwithstanding CRISPR), unparalleled opportunities exist for 
repurposing and adapting the principles of MR to new approaches that may lead to novel 
prospects for the translation of GWAS discoveries. Such applications are expected to lead to 
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advances not only in elucidating the causes and consequences of disease, but as in the current 




The Medical Research Council (MRC) and the University of Bristol fund the MRC Integrative 
Epidemiology Unit (MC_UU_12013/1, MC_UU_12013/9). MVH works in a unit that receives 
funding from the UK Medical Research Council and is supported by a British Heart Foundation 
Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for 








1. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: A guide, 
glossary, and checklist for clinicians. BMJ 2018;362:k601. 
2. Davey Smith G, Ebrahim S. 'Mendelian randomization': Can genetic epidemiology contribute 
to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22. 
3. Holmes MV, Davey Smith G. CETP inhibition and ADCY9 genotype: Evidence of a qualitative 
pharmacogenetic interaction in cardiovascular disease? bioRxiv 2018 Jun 06  as doi: 
https://doi.org/10.1101/336875. 
4. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Genomic risk 
prediction of coronary artery disease in 480,000 adults: Implications for primary 
prevention. J Am Coll Cardiol 2018;72:1883-93. 
5. Bovijn J, Jackson L, Censin J, Chen CY, Laisk T, Laber S, et al. GWAS identifies risk locus for 
erectile dysfunction and implicates hypothalamic neurobiology and diabetes in etiology. 
Am J Human Genet 2019 (In Press) https://doi.org/10.1016/j.ajhg.2018.11.004. 
Available online at: https://marlin-prod.literatumonline.com/pb-
assets/journals/society/ajhg/AJHG2687.pdf 
6. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between alcohol 
and cardiovascular disease: Mendelian randomisation analysis based on individual 
participant data. BMJ 2014;349:g4164. 
7. Dyer O. $100m alcohol study is cancelled amid pro-industry "bias". BMJ 2018;361:k2689. 
8. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian 
randomization studies. Hum Mol Genet 2018;27:R195-R208. 
9. Mohammadi-Shemirani P, Sjaarda J, Gerstein HC, Treleaven DJ, Walsh, Mann JF, et al. A 
Mendelian randomization-based approach to identify early and sensitive diagnostic 
biomarkers of disease. Clin Chem 2018 
10. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base platform 
supports systematic causal inference across the human phenome. Elife 2018 May 30;7. 
pii:e34408. 
  6 
11. Holmes MV, Ala-Korpela M, Davey Smith G. Mendelian randomization in cardiometabolic 
disease: Challenges in evaluating causality. Nat Rev Cardiol 2017;14:577-90. 
12. Holmes MV, Davey Smith G. Problems in interpreting and using GWAS of conditional 
phenotypes illustrated by 'alcohol GWAS'. [Epub ahead of print] Mol Psychiatry 2018 
Mar 8 as doi: 10.1038/s41380-018-0037-1. 
13. Davey Smith G, Paternoster L, Relton C. When will Mendelian randomization become 
relevant for clinical practice and public health? JAMA 2017;317:589-91. 
14. Cook NR. Statistical evaluation of prognostic versus diagnostic models: Beyond the ROC 
curve. Clin Chem 2008;54:17-23. 
15. Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS, Davey Smith G. Biomarker de-
Mendelization: Principles, potentials and limitations of a strategy to improve biomarker 
prediction by reducing the component of variance explained by genotype. bioRxiv 2018 








Figure 1. Potential scenarios of biomarker associations of a genetic risk score for disease. The 
seven scenarios are described in the main text. Purple cloud call-outs elucidate whether the 
biomarker is likely to have a role in disease prediction and/or whether it represents a potential 
therapeutic target for the treatment and/or prevention of disease.  GRS = genetic risk score.  
 
 
 
 
